EFFECTS OF FIXED COMBINATION OF LISINOPRIL PLUS HYDROCHLOROTHIAZIDE ON REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION: AN OPENED, MULTI-CENTRE, PROSPECTIVE CLINICAL TRIAL

1. VJEKOSLAV GERC, Clinic for Heart Diseases and Rheumatism, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina
2. BEGLER BEGOVIĆ*, Institute for Clinical Pharmacology, Clinics Center University of Sarajevo, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina
3. MIDHAT VEHABOVIĆ, Bosnalijek dd, Jukićeva 53, 71000 Sarajevo, Bosnia and Herzegovina
4. LEONID GEORGEVICH VORONKOV, Institute of Cardiology of Academy of Medical Sciences of Ukraine, 03126 Kiev, Ukraine
5. ELEONORA VATAMAN, Scientific Departments of Medicine, MD-2000 Chisinau, Moldova
6. LJILJANA MUSIĆ, Clinic for Heart Diseases, Clinical Center of Montenegro, Ljubljanska bb, 81000 Podgorica, Montenegro
7. MARKO BUKŠA, Clinic for Heart Diseases and Rheumatism, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina
8. ZUMRETA KUŠLJUGIĆ, Department of Cardiology, University Clinical Center Tuzla, Trnovac bb, 75000 Tuzla, Bosnia and Herzegovina
9. FAHIR BARAKOVIĆ, Department of Cardiology, University Clinical Center Tuzla, Trnovac bb, 75000 Tuzla, Bosnia and Herzegovina
10. VERA IOSIFOVNA TCHELJUKO, City Hospital № 8, 61000 Kharkov, Ukraine
11. ALEXANDER IVANOVICH DYADUK, City Hospital № 1, 83000 Donetsk, Ukraine
12. SVELTANA ALEKSEEVNA ANDRIEVSKAJA, Regional Cardiological Clinic, 65000 Odessa, Ukraine
13. ANDREY EDUARDOVICH BAGRIJ, City Hospital № 1, 83000 Donetsk, Ukraine
14. SERGEY NIKOLAIEVICH POLIVODA, Regional Clinical Hospital, 69000 Zaporozhye, Ukraine
15. ALEKSANDAR LAZAREVIĆ, Clinic for Internal Diseases, Clinical Centre, 12 beba 1, 51000 Banja Luka, Bosnia and Herzegovina
16. BOŽIDARKA KNEŽEVIĆ, Clinic for Heart Diseases, Clinical Center of Montenegro, Ljubljanska bb, 81000 Podgorica, Montenegro
17. FAIK HIMA, Internal Clinic UCC Pristina, 10 000 Pristina, Kosovo
* Corresponding author
ABSTRACT

The aim of this trial was to examine the effects of antihypertensive fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension. We included 297 patients in our trial, aged 54.65±19.6 years, with treated or untreated hypertension and with high risk of cardiac events, in an opened trial of therapy based on lisinopril plus hydrochlorothiazide. Patients from five European countries were followed up for a period of 12 weeks. Duration of treatment was 12 weeks. We adjusted daily doses of lisinopril plus hydrochlorothiazide after every clinical examination and recorded adverse effects of drugs.

In the beginning and after 12 weeks of treatment, 277 patients (93.2%) underwent 2-dimensional echocardiography and there were 186 patients evaluated for efficacy of treatment on left ventricular hypertrophy (LVH). We recorded a regression of index mass LVH (168.56 ± 161.51 g/m²; P < 0.0001), and regression was something more in women vs men. We recorded average reduction of LV mass index for patients with LVH (N = 186) by 7.05 g/m² (4.18%) in all patients, by 6.73 g/m² (3.93%) in men and 7.27 g/m² (4.37%) in women. The proportion of patients who attained a regression of left ventricular mass tended to be greater in men (54.55% vs 53.21%). This research has proved regression of LVH in more than 53% patients after using fixed combination of lisinopril plus hydrochlorothiazide.

KEY WORDS: essential hypertension, left ventricular hypertrophy, lisinopril, hydrochlorothiazide

INTRODUCTION

Left ventricular (LV) hypertrophy is a strong predictor of cardiovascular morbidity and mortality in the general population, and particularly in patients with hypertension. Regression of LV hypertrophy by antihypertensive therapy appears to reduce the risk for developing cardiovascular complications. Consequently, reversal of LVH is an important goal of antihypertensive therapy. Angiotensin converting enzyme (ACE) inhibitors reduce LV mass to a greater extent than other antihypertensive drug classes, when equivalent levels of blood pressure reduction are achieved. This provides strong evidence for the role of the renin–angiotensin–aldosterone system in the development or maintenance of LV hypertrophy.

The aim of this trial was to examine influence of fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension.

PATIENTS AND METHODS

The trial was open, multi-centre, prospective, clinical trial lasting 12 weeks per patient. Totally 277 subjects with essential hypertension were included in the trial, both genders aged 35 to 65 years. Total duration of the trial per patient was 12 weeks. The following examinations and measuring were performed prior to including into trial: Blood pressure and pulse

Electrocardiogram (Sokolow – Lyons; Cornell)

Echocardiography (of heart obligatory LVMI – left ventricle mass index)

Average age of all patients included into trial was 54.65±19.6 years, and 157 women and 140 men were included into trial. On the basis of initial results of echocardiography we found 186 patients evaluated for efficacy of treatment on left ventricular hypertrophy. Average duration of illness for all patients was around 9.57±8.1 years.

In addition to high blood pressure, increased body weight (body mass index 25.0–29.9) was present in 39% women and 47.5% men, and obesity (body mass index above 30) was present in 41.5% women and 31% men, so that completely 19.5% women and 21.5% men had optimal body weight.

Statistical processing of results

Statistical analyses were made in statistical programme MedCalc for Windows, version 9.2.1.0 (MedCalc Software, Mariakerke, Belgium). Results are shown through the usual descriptive statistics and paired samples T-test.

<table>
<thead>
<tr>
<th>Age (SD)</th>
<th>Women</th>
<th>Men</th>
<th>TOTALLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>55.26 (9.28)</td>
<td>55.05 (9.92)</td>
<td>54.69 (9.59)</td>
<td></td>
</tr>
<tr>
<td>Weight kg (SD)</td>
<td>78.32 (11.09)</td>
<td>88.39 (14.9)</td>
<td>82.73 (12.17)</td>
</tr>
<tr>
<td>Height cm (SD)</td>
<td>174.82 (6.67)</td>
<td>174.20 (13.72)</td>
<td>170.12 (8.66)</td>
</tr>
<tr>
<td>BMI kg/m² (SD)</td>
<td>28.83 (3.39)</td>
<td>28.26 (3.48)</td>
<td>28.56 (3.27)</td>
</tr>
<tr>
<td>Systolic BP (SD)</td>
<td>161.87 (16.47)</td>
<td>161.86 (13.21)</td>
<td>161.82 (15.02)</td>
</tr>
<tr>
<td>Diastolic BP (SD)</td>
<td>99.35 (6.93)</td>
<td>97.29 (7.02)</td>
<td>98.31 (6.66)</td>
</tr>
</tbody>
</table>

| Left ventricular hypertrophy (LVH) | 109 | 77 | 186 |
As an estimate of significance of differences between the average measuring, significance was taken of $P<0.05$.

**Methods**

The study was done in compliance with Guidelines for Good Clinical Practice and Helsinki Declaration of the World Medical Association and all patients provided written informed consent before the beginning of the study. This 12-week opened prospective clinical trial was done at 12 centres in five European countries. After 2 weeks of washout period for patients receiving anti-hypertensive medications, patients entered the study. Patients were followed up for period of 12 weeks and duration of treatment was 12 weeks. We adjusted daily doses of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) after every clinical examination and recorded adverse effects of drugs. LVH was documented by echocardiogram (Devereux criteria [LV mass index $\geq 134\ g/m^2$ for men and $\geq 110\ g/m^2$ for women]) (1).

**RESULTS**

Total number of 297 patients (ITT) were included in the trial, 277 patients completely finalised the trial (by trial protocol, PP, 93.27%), and for 20 patients we did not make analyses of echocardiography (6.73%). Reasons for giving up the trial are not related to side-effects of drugs, nor intolerance to medicines, but they are linked to patients’ non-cooperation in the trial (e.g. irregular coming to control check-ups and irregular administration of therapy). We made analysis of blood pressure for all included patients ($n=297$) in the trial, and average lowering was accomplished for sys/dia BP $33.22\ mmHg/19.17\ mmHg$, or by 20.56%/19.43%. Analysis of results has shown that we obtained the best results in medication’s effect on the systolic blood pressure, where lowering was accomplished in all the groups from 15.36% to 26.57%, while differences between baseline and final values of diastolic blood pressure by groups were from 15.66% to 22.28%. Treatment with

### TABLE 2. Echocardiography results of all patients included in trial (N=277)

<table>
<thead>
<tr>
<th>Echocardiography parameters</th>
<th>Baseline (SD)</th>
<th>Final (SD)</th>
<th>Difference (SD)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left ventricular internal diameter at end diastole – LVIDd (mm)</td>
<td>50.48 (5.62)</td>
<td>50.32 (5.59)</td>
<td>0.16 (1.89)</td>
<td>0.1709 NS</td>
</tr>
<tr>
<td>Posterior wall thickness at end diastole PWd (mm)</td>
<td>11.20 (1.95)</td>
<td>10.92 (1.76)</td>
<td>0.28 (1.10)</td>
<td>$P &lt; 0.0001^*$</td>
</tr>
<tr>
<td>Septal wall thickness at end diastole IVSd (mm)</td>
<td>11.63 (2.14)</td>
<td>11.49 (2.06)</td>
<td>0.14 (0.96)</td>
<td>0.0140 *</td>
</tr>
<tr>
<td>Left ventricular mass index (g/m²)</td>
<td>147.49 (47.17)</td>
<td>142.86 (44.83)</td>
<td>4.63 (15.72)</td>
<td>$P &lt; 0.0001^*$</td>
</tr>
</tbody>
</table>

Legend: SD – standard deviation, $^*P<0.05$. 

**FIGURE 1. Changes in left ventricular mass index (g/m²) of all patients included in trial**

Legend: ALL IMLV 1 – left ventricular mass index of all patients, first measure.
ALL IMLV 2 – left ventricular mass index of all patients, second measure.
fixed combinations of lisinopril plus hydrochlorothiazide in all patients resulted in mean change of LVH mass index $4.63 \pm 15.72$ g/m\(^2\) ($p < 0.0001$) (Table 2; Figure 1). Treatment with fixed combinations of lisinopril plus hydrochlorothiazide in all patients with LVH resulted in mean change of LVH mass index $7.06 \pm 16.54$ g/m\(^2\) ($p<0.0001$) (Table 3; Figure 2). Treatment with fixed combinations of lisinopril plus hydrochlorothiazide in men with LVH resulted in mean change of LVH mass index $6.77 \pm 16.49$ g/m\(^2\) ($p = 0.0006$) (Table 4; Figure 3). Treatment with fixed combinations of lisinopril plus hydrochlorothiazide in women with LVH resulted in mean change of LVH mass index $7.28 \pm 16.64$ g/m\(^2\) ($p < 0.0001$) (Table 5; Figure 4).

We recorded average reduction of left ventricular mass index for patients with LVH (N=186) by 7.05 g/m\(^2\) (4.18%) in all patients, by 6.73 g/m\(^2\) (3.93%) in men and 7.27 g/m\(^2\) (4.37%) in women. The proportion of patients who attained a regression of left ventricular mass tended to be greater in men (54.55% vs 53.21%). This research has proved regression of LVH in more than 53% patients after using fixed combination of lisinopril plus hydrochlorothiazide.

### Table 3. Echocardiography results of patients with LVH included in trial (n=186)

<table>
<thead>
<tr>
<th>Echocardiography parameters</th>
<th>Baseline (SD)</th>
<th>Final (SD)</th>
<th>Difference (SD)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left ventricular internal diameter at end diastole – LVIDd (mm)</td>
<td>51.87 (5.29)</td>
<td>51.69 (5.14)</td>
<td>-0.18 (1.86)</td>
<td>0.1919</td>
</tr>
<tr>
<td>Posterior wall thickness at end diastole PWtd (mm)</td>
<td>11.96 (1.76)</td>
<td>11.56 (1.59)</td>
<td>-0.41 (1.19)</td>
<td>P &lt; 0.0001 *</td>
</tr>
<tr>
<td>Septal wall thickness at end diastole IVSd (mm)</td>
<td>12.48 (1.95)</td>
<td>12.22 (1.96)</td>
<td>-0.27 (0.95)</td>
<td>0.0002 *</td>
</tr>
<tr>
<td>Left ventricular mass index (g/m(^2))</td>
<td>168.53 (42.42)</td>
<td>161.86 (41.95)</td>
<td>7.06 (16.54)</td>
<td>P &lt; 0.0001*</td>
</tr>
</tbody>
</table>

### Table 4. Echocardiography results of men with LVH included in trial (n=77)

<table>
<thead>
<tr>
<th>Echocardiography parameters</th>
<th>Baseline (SD)</th>
<th>Final (SD)</th>
<th>Difference (SD)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left ventricular internal diameter at end diastole – LVIDd (mm)</td>
<td>53.52 (5.07)</td>
<td>53.60 (4.99)</td>
<td>0.08 (2.11)</td>
<td>0.7300</td>
</tr>
<tr>
<td>Posterior wall thickness at end diastole PWtd (mm)</td>
<td>12.12 (1.50)</td>
<td>11.71 (1.48)</td>
<td>0.41 (1.19)</td>
<td>0.0035 *</td>
</tr>
<tr>
<td>Septal wall thickness at end diastole IVSd (mm)</td>
<td>12.68 (1.70)</td>
<td>12.23 (1.66)</td>
<td>-0.44 (0.81)</td>
<td>P &lt; 0.0001*</td>
</tr>
<tr>
<td>Left ventricular mass index (g/m(^2))</td>
<td>171.37 (36.85)</td>
<td>164.59 (38.50)</td>
<td>6.77 (16.69)</td>
<td>0.0006*</td>
</tr>
</tbody>
</table>

**FIGURE 2. Changes in left ventricular mass index (g/m\(^2\)) of patients with LVH**

Legend: ALL LVH 1 – left ventricular mass index of all patients with LVH, first measure.
ALL LVH 2 – left ventricular mass index of all patients with LVH, second measure.
Discussion

LV hypertrophy is an important determinant of cardiovascular morbidity and mortality (2,3), and reduction of LV hypertrophy with antihypertensive therapy reduces the number of cardiovascular events (4,5). One of the most important prognostic factors in hypertension is electrocardiographic or echocardiographic parameters.
graphic left ventricular hypertrophy, with the latter already present in as many as 25% of patients with newly diagnosed hypertension. In a multicenter observational study of hypertensive patients with no prior history of cardiovascular or renal disease, echocardiographic left ventricular hypertrophy at baseline was accompanied by a three-fold increase in the cumulative 4-year incidence of cardiovascular events (6). Because of the firmly established prognostic significance of left ventricular hypertrophy, numerous studies have examined the ability of antihypertensive therapy to cause regression of left ventricular hypertrophy. Meta-analyses estimate that left ventricular mass can be reduced by 11 to 12% with an ACE inhibitor, ARB, or CCB; 8% with a thiazide diuretic; but only 5% with a β-blocker. In contrast, in patients undergoing valve replacement for aortic stenosis, nearly complete surgical normalization of systolic load results in a rapid and dramatic 35% reduction in left ventricular mass. The comparatively disappointing effects of the antihypertensive drug trials are likely to be related to the incomplete normalization of systolic load in monotherapy trials (6). Despite the impressive body of randomized clinical trial data, it remains to be determined whether even intensive antihypertensive therapy can completely normalize the excessive risks of cardiovascular and renal disease associated with untreated hypertension. In a large hypertensive referral clinic in Gothenburg, Sweden, treatment of hypertension in initially middle-aged men to a goal of 160/90 to 95 mm Hg with diuretics and β-blockers for 20 years did not completely normalize the risk of myocardial infarction. The persistently elevated risks in the treated patients were related to the existence of associated risk factors, such as cigarette smoking and elevated blood lipid levels, and emphasize the need for global risk reduction and larger reductions in blood pressure. Randomized trials have not yet established whether even lower blood pressure goals than those presently endorsed would produce further reductions in cardiovascular morbidity and mortality and in the risk of end-stage renal disease. Because of their relatively short duration (typically less than 5 years), randomized trials underestimate the life-time protection against premature disability and death afforded by several decades of antihypertensive therapy in clinical practice. In the Framingham Heart Study, treatment of hypertension for 20 years in middle-aged adults reduced total cardiovascular mortality by 60%, which is considerably greater than the results of most randomized trials despite the less intense treatment guidelines when therapy was initiated in the 1950s to 1970s (6). We used fixed combination of two antihypertensives lisinopril and hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina). The efficacy can be seen in the reduction of systolic and diastolic pressure, and this research has proved regression of LVH in more than 86% patients after using fixed combination of lisinopril plus hydrochlorothiazide.

CONCLUSION

This research has proved good efficacy and tolerability of fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) and in more than 53% patients recorded regression of left ventricular hypertrophy.

Separate

This trial is supported by pharmaceutical company Bosnalijek dd. Jukićeva 53, Sarajevo, Bosnia and Herzegovina.

REFERENCES